New Report Examines the Impact of Disinformation on Public Health Outcomes
MANILA, PHILIPPINES, May 22, 2025 / EINPresswire.com / -- In an era of widespread access to information, the growing influence of disinformation presents complex challenges for public health. A new analysis, The Silent Threat: How Disinformation Harms Public Health, explores the potential effects of misleading information on public trust and the delivery of health guidance, and recommends strategies for evidence-based responses.
The report outlines how disinformation—defined as the intentional spread of false or misleading information—can create confusion and reduce adherence to health recommendations. It also suggests that when public health decisions appear to be shaped by factors other than scientific evidence, confidence in health systems can diminish, potentially affecting outcomes.
'Disinformation differs from simple misinformation in that it is intentional and designed to mislead,' said Clarisse Virgino, CAPHRA Philippines representative. 'It can gain traction particularly when there are inconsistencies in public health messaging or when individuals perceive a disconnect between official guidance and their personal experiences.'
The analysis draws on examples such as the COVID-19 pandemic, where varying information and debates over policy led to public skepticism. Similar concerns are noted in areas such as tobacco harm reduction, where conflicting narratives may complicate decision-making for individuals seeking to understand their options.
The report highlights that disinformation may disproportionately impact vulnerable populations, including marginalized communities that already encounter barriers to accessing healthcare and accurate information. These dynamics can exacerbate existing health inequities.
The authors advocate for public health policy to remain firmly rooted in evidence and emphasize the importance of clear, consistent communication. They recommend that public health leaders focus on maintaining transparency and rebuilding trust as fundamental components of effective health promotion and protection.
The report concludes by calling on public health authorities to prioritize the delivery of accurate information and to ensure that the needs and welfare of the population remain central to decision-making processes.
To read the full position paper, please visit: https://bit.ly/3F6vjGX
N. E. Loucas
Coalition of Asia Pacific Tobacco Harm Reduction Advocates
[email protected]
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
2 dead, 58 sick amid Legionnaires' disease outbreak in New York City
NEW YORK — A second person has died and 58 others have fallen ill amid an outbreak of Legionnaires' disease wreaking havoc in the Harlem area, New York City health officials announced. It marks an increase from previous figures released by the New York City Health Department on Thursday, when there was a total of 22 reported cases and a single death linked to the growing cluster. In a statement on Monday, acting New York City health commissioner Dr. Michelle Morse urged anyone in the area suffering from flu-like symptoms to 'contact a health care provider as soon as possible.' 'It is especially important for people at higher risk — including those ages 50 and older, cigarette smokers, and people with chronic lung disease or compromised immune systems — to get care if they have symptoms,' Morse added. Legionnaires' disease is a type of pneumonia caused by the bacteria Legionella, which grows in warm water. According to the New York City Health Department, it 'can be caused by plumbing systems where conditions are favorable for Legionella growth, such as cooling towers, whirlpool spas, hot tubs, humidifiers, hot water tanks and evaporative condensers of large air-conditioning systems.' And while it cannot be passed from person to person, it can be contracted by breathing in any contaminated water vapor. The New City Department of Health is investigating the cluster. Since the outbreak was initially detected on July 25; crews have repaired 'the 11 cooling towers with initial positive screening results showing the presence of Legionella pneumophila, a type of bacteria that causes Legionnaires' disease.'
Fox News
3 hours ago
- Fox News
Deadly bacterial outbreak infects dozens in city neighborhood as officials sound alarm
An outbreak of bacterial pneumonia has infected dozens of people in New York City, according to health officials. A total of 58 people have been diagnosed with Legionnaires' disease, a type of pneumonia caused by the bacteria Legionella. Two people have died, the NYC Health Department confirmed in an August 4 news release. The cluster of cases is concentrated in Central Harlem and bordering communities (zip codes 10027, 10030, 10035, 10037 and 10039). "Anyone in these zip codes with flu-like symptoms should contact a healthcare provider as soon as possible," said Acting Health Commissioner Dr. Michelle Morse in the health department's alert. Legionnaires' is usually found in lakes, streams and other freshwater environments. However, it can grow and spread indoors via shower heads, sink faucets, hot tubs, water features/fountains, plumbing systems and other water systems where conditions are favorable for the Legionella bacteria to grow, according to the Centers for Disease Control and Prevention (CDC). When people swallow or breathe in droplets of water that contain Legionella, they can potentially become ill with Legionnaires' disease. The disease is not typically spread from person to person, per the CDC. In the case of the New York City outbreak, the health department directed the state to perform remediation for 11 cooling towers that tested positive for the bacteria. "Legionnaires' disease can be effectively treated if diagnosed early, but New Yorkers at higher risk, like adults aged 50 and older and those who smoke or have chronic lung conditions, should be especially mindful of their symptoms and seek care as soon as symptoms begin," Morse added. Symptoms of Legionnaires' disease usually show up between two and 14 days after exposure. The condition usually causes flu-like symptoms, including cough, chills, muscle aches, fever or difficulty breathing. Some patients may also experience nausea, diarrhea and confusion, the CDC noted. "The nature of the symptoms is not necessarily what differentiates Legionella from other causes, but history of exposure from 'human-made reservoirs,' though this may be hard to discern early on in infection and/or in an outbreak," said Goodyear. Those who have any of these symptoms should seek medical attention immediately, the CDC advises. Groups at highest risk include smokers, people 50 and older, those with chronic lung disease and people who are immunocompromised, according to health officials. "Other risk factors include advancing age, cardiovascular disease, obesity and compromised immune systems," Dr. Nathan Goodyear, medical director of Brio-Medical in Arizona, previously told Fox News Digital. Around 10% of people who contract Legionnaires' disease will die from complications. Diagnosis of Legionnaires' disease is made via chest X-ray, urine test and lab analysis of a phlegm sample. Most people with the disease will recover with a course of antibiotics. In some patients, however, serious illness can lead to lung failure or death, per the CDC. Around 10% of people who contract Legionnaires' disease will die from those complications — and the mortality risk rises to 25% for those who get Legionnaires' while staying in a healthcare facility. "Treatment needs to be early and aggressive," Goodyear told Fox News Digital. "Legionella infection is an intracellular infection that requires antibiotic treatment." Antibiotics that are appropriate for Legionella infection include Levofloxacin and Azithromycin. "Therapy can be prescribed orally in healthy individuals … but intravenous antibiotics often prove to be the initial option for treatment secondary to the pathogenicity of the disease," Goodyear said. Currently, there are no vaccines for Legionnaires' disease. The best strategy to prevent infection is to reduce the growth and spread of the Legionella bacteria. For more Health articles, visit The CDC recommends that building owners and managers use a water management program to reduce the risk. To prevent serious illness from Legionnaires', Goodyear recommends that all smokers kick the habit, and also emphasizes the need to "aggressively support" chronic pulmonary disease.
Yahoo
3 hours ago
- Yahoo
JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio's DEX-G2 Blood Test For Early Detection of Gastric Cancer
SAN ANTONIO, Aug. 5, 2025 /PRNewswire/ -- A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance of the Destinex assay, a novel liquid biopsy that serves as the foundation for Cizzle Bio's DEX-G2 blood-based assay for early detection of gastric cancer—one of the world's deadliest malignancies. The study's findings validate the clinical utility of DEX-G2 as a minimally invasive, clinically actionable tool to detect gastric cancer at its earliest and most treatable stages, when timely intervention can significantly improve outcomes and save lives. The DESTINEX study, conducted at leading cancer centers in Japan and South Korea, evaluated a signature panel of microRNAs derived from exosomes and cell-free serum. The study analyzed 809 serum specimens from 480 participants, including patients with gastric cancer and matched controls. Using machine learning to refine and validate the assay, researchers demonstrated exceptional diagnostic accuracy for early-stage gastric cancer. The study was led by Ajay Goel, Ph.D., AGAF, an internationally recognized leader in cancer biomarker research and the developer of the Destinex assay. Goel also serves as scientific advisor to Cizzle Bio and is chair of the Department of Diagnostics and Experimental Therapeutics at City of Hope Comprehensive Cancer Center, where he led the development of the Destinex assay into the DEX-G2 blood test that Cizzle Bio is now advancing for near-term commercial launch. "The publication of this study in JAMA Surgery is a critical milestone, not only for our scientific team but also for the future of early gastric cancer detection," said Goel. "By combining the sensitivity of cell-free microRNAs with the specificity of exosomal markers, Destinex—and now DEX-G2—offers a minimally invasive, accessible, and highly accurate method for detecting gastric cancer at a stage when outcomes can be dramatically improved." In the study, the Destinex assay achieved an area under the curve (AUC) of 96.8% in the validation cohort, with a sensitivity of 95.0% for detecting early-stage (pT1) gastric cancer. These findings underscore the assay's strength as a minimally invasive tool for identifying gastric cancer early when it is most curable. The assay achieved high sensitivity and specificity in distinguishing individuals with gastric cancer from those without the disease, confirming its potential not only as a minimally invasive screening tool but also to significantly improve patient outcomes through earlier detection and intervention. A Pressing Clinical Need Gastric cancer is the third leading cause of cancer-related deaths worldwide, mainly due to delayed diagnosis. Globally, more than 60% of gastric cancer cases are diagnosed at advanced stages, when curative treatment is no longer an option and prognosis is poor. Endoscopic screening has helped reduce mortality in high-incidence countries such as Japan and Korea, but its cost, invasiveness, and limited availability make it impractical for widespread use in low-incidence regions. Minimally invasive blood-based tests like DEX-G2 have the potential to fill this gap. The Destinex assay, the scientific basis of DEX-G2, demonstrated outstanding sensitivity and specificity for detecting early-stage (T1) gastric cancer, and its diagnostic performance remained robust across tumor stages and patient subgroups. The study also showed a significant drop in biomarker levels after surgical tumor removal, confirming the assay's tumor specificity. Read the full JAMA Surgery study here: "This study reinforces the scientific credibility and clinical utility of the technology behind DEX-G2," said Bill Behnke, CEO of Cizzle Bio. "We are proud to advance this innovation into clinical practice, where it has the potential to make earlier detection a reality for patients who currently have few options for early detection." From Discovery to Clinical Application Cizzle Bio is advancing its DEX-G2 test, based on the Destinex assay, for near-term commercial deployment in CLIA-certified laboratories. It is intended to support clinicians in detecting gastric cancer earlier, particularly in primary care and gastroenterology settings where endoscopy may not be accessible or practical. The company holds a worldwide exclusive license for DEX-G2 and is actively pursuing commercialization in both U.S. and global markets, with a focus on reaching populations where gastric cancer is often diagnosed too late for curative treatment. About Cizzle Bio Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by advancing biomarker-based blood tests, starting with early detection of lung and gastric cancers. Our goal is to empower patients, equip clinicians, and improve outcomes through innovation, compassion, and life-saving solutions. We hold exclusive licensing rights for our groundbreaking CIZ1B biomarker test in the United States, Canada, and the Caribbean and a worldwide exclusive license for our DEX-G2 biomarker gastric cancer test. Cizzle Bio is commercializing both tests for U.S. clinical Media Contact: Yolanda Heibergeryolanda@ View original content to download multimedia: SOURCE Cizzle Bio
